Physician profile
Henry Cheng
NPI 1811276181
$15,481.74
in general payments reported to CMS, 2019-2025
46 companies · $4,678 in 2025
The $4,678 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,218 · 2020: $251 · 2021: $567 · 2022: $2,041 · 2023: $2,495 · 2024: $3,231 · 2025: $4,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,379.84 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,866.98 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $2,455.03 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,642.94 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $893.05 | 2022-2024 | Austedo Xr, Ajovy, Uzedy |
| Glaxosmithkline, LLC. | $737.82 | 2019-2024 | Arexvy |
| Pfizer INC. | $624.32 | 2019-2023 | |
| Gilead Sciences, INC. | $400.00 | 2024-2025 | Vemlidy, Epclusa |
| Phathom Pharmaceuticals, INC. | $392.96 | 2024-2025 | Voquezna |
| Antares Pharma, INC. | $386.57 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Abbvie INC. | $378.10 | 2022-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $368.34 | 2020-2025 | Emgality, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $335.82 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $332.48 | 2019-2020 | |
| Dexcom, INC. | $300.97 | 2025 | Dexcom G6 Transmitter |
| Scilex Pharmaceuticals INC. | $277.16 | 2024 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.